In recent years, there has been an increase in the number of overdoses that involve a psychostimulant, such as methamphetamine, cocaine, or prescription. In response to growing rates of stimulant misuse, addiction, and overdose, stakeholders across the U.S. health care system are working to implement strategies designed to ensure that patients with stimulant use disorder are treated appropriately. For public policy, regulatory, and clinical decision-makers, understanding the shifting trends in addiction is critical to improving patient health outcomes and public health. Currently, there are no pharmacological treatments approved by the U.S. Food and Drug Administration for stimulant use disorder. New therapies are needed to address treatment gaps for patients with stimulant use disorder.
Through a cooperative agreement with the U.S. Food and Drug Administration, this public workshop will examine the complexities of stimulant use disorder with a focus on methamphetamine and cocaine abuse. The goals of this workshop are to explore emerging trends in illicit and prescription stimulant abuse, review drug development paradigms for novel treatments, and explore potential innovative therapies for stimulant use disorder. Participants will discuss future directions for drug development and regulation as well as strategies for patient engagement. This meeting will bring together experts and key stakeholders from federal agencies, academia, and professional organizations. This workshop will lay the groundwork for understanding this complex landscape and promoting the exchange of innovative ideas to advance the development of novel therapies for stimulant use disorder.